01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished an 8-K on January 12, 2026 with preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025.
The Company estimates net product revenue of $146.0 milliona for the fourth quarter of 2025 and $362.4 million for the full year 2025, and approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. The filing states that the audit of the consolidated financial statements is ongoing and could change these figures. The filing also furnishes the press release and J.P.
Morgan Healthcare Conference slides, which center on Attruby (acoramidis), the company's commercial product for ATTR-CM. The release reports 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, and the slides estimate Attruby's share of new-to-brand prescriptions (NBRx) at more than 25%b. The company also announced a new monoclonal antibody depleter program for ATTR-CM, expected to enter the clinic in 2027–2028.
Pipeline updates include positive interim results from the Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9, with a stated 2.6-point benefit on the North Star Assessment for Limb-Girdle Type Muscular Dystrophies (NSAD) versus placebo at 12 months, and an FDA recommendation to orient the NDA toward traditional approval, with NDA submission planned for the first half of 2026. The company also reported encaleret's CALIBRATE Phase 3 results in ADH1, planned NDA submission in the first half of 2026, and the start of the RECLAIM-HP Phase 3 trial in chronic hypoparathyroidism in summer 2026. Topline results for the PROPEL 3 Phase 3 study of infigratinib in achondroplasia are expected by the end of the first quarter of 2026.
02—Key points
Key Highlights
- Preliminary unaudited net Attruby product revenue of $146.0 million for Q4 2025 and $362.4 million for full year 2025; audit still ongoing and figures could change.
- Approximately $587.5 million in cash, cash equivalents and marketable securities as of December 31, 2025, which the company says supports potential launches of three additional medicines globally.
- Attruby had 6,629 unique patient prescriptions from 1,632 prescribers as of December 31, 2025, and the slides estimate more than 25% NBRx share.
- New ATTR-CM antibody depleter program announced, expected to advance into the clinic in 2027–2028.
- BBP-418 (LGMD2I/R9): FDA recommended orienting the NDA toward traditional full approval; NDA submission planned for first half of 2026.
- Encaleret: CALIBRATE Phase 3 in ADH1 reported a 76% responder rate at Week 24; NDA planned for first half of 2026, and RECLAIM-HP Phase 3 in chronic hypoparathyroidism to start in summer 2026.
- Infigratinib: LPLV reached for PROPEL 3 Phase 3 in achondroplasia, with topline results expected by end of Q1 2026.
03—Questions
Frequently Asked Questions
What revenue did BridgeBio report for the fourth quarter and full year 2025?
The company estimates net product revenue of $146.0 million for the quarter ended December 31, 2025 and $362.4 million for the fiscal year ended December 31, 2025. These figures are preliminary and unaudited, and the audit of the consolidated financial statements is ongoing and could change them.
How much cash does BridgeBio have?
The company estimates approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025. The filing states this is preliminary and subject to the ongoing audit.
What are the near-term regulatory and clinical catalysts?
The company plans to submit NDAs for BBP-418 and encaleret in the first half of 2026, expects PROPEL 3 topline results for infigratinib by the end of Q1 2026, and plans to start the RECLAIM-HP Phase 3 trial of encaleret in summer 2026. The slides also show BBP-418 FDA approval and launch in the second half of 2026 and encaleret FDA approval and launch in the first half of 2027.
What is the new ATTR-CM program?
BridgeBio announced a new monoclonal antibody depleter program to explore ATTR-CM disease reversal by clearing existing amyloid deposits, in contrast to Attruby, which stabilizes TTR tetramers. The program is expected to advance into the clinic in 2027–2028.
04—Continue